P0F Stock Chart & Stats
$0.70
$0.07(11.80%)
―
--
Day’s Range― - ―
52-Week Range$0.36 - $0.73
Previous CloseN/A
VolumeN/A
Average Volume (3M)128.00
Market Cap
€345.93M
Enterprise Value$2.34K
Total Cash (Recent Filing)€378.40M
Total Debt (Recent Filing)€68.80M
Price to Earnings (P/E)―
Beta-0.62
Next Earnings
Nov 06, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.01
Shares Outstanding464,947,240
10 Day Avg. Volume0
30 Day Avg. Volume128
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)5.81
Price to Sales (P/S)31.51
P/FCF Ratio-7.32
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€2.91Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.04
Revenue Forecast (FY)€52.75M
Bulls Say, Bears Say
Bulls Say
Rare-disease SpecializationConcentration on late-stage orphan drugs targets serious conditions where unmet need is high. This specialization can support focused development decisions, differentiated regulatory positioning, and potential commercialization value if lead programs achieve durable adoption.
Revenue GrowthRevenue growth indicates that the company is making commercial progress despite its early-stage biotech economics. A larger revenue base can improve operating leverage over time and provide a stronger platform for funding development and commercialization of its rare-disease portfolio.
Moderate LeverageModerate leverage and a sizable equity base reduce the immediate pressure from debt obligations. This gives management more financial flexibility than a highly leveraged structure while the company works to improve profitability and scale its commercial operations.
Bears Say
Deep Operating LossesExtremely negative operating and net margins show that current expenses remain far above the revenue base. Until revenue scales substantially or costs decline, the company is unlikely to achieve sustainable earnings, leaving its business model dependent on continued funding.
Heavy Cash BurnLarge negative operating and free cash flow demonstrate that the business is not self-funding. Persistent cash consumption can restrict investment flexibility and increase reliance on external financing, especially if commercialization or revenue growth takes longer than expected.
Loss-driven Capital ErosionNegative returns on equity indicate that the existing capital base is not yet generating productive returns. If losses continue, accumulated deficits may erode equity and weaken the company’s capacity to fund development internally, even with moderate leverage.
Egetis Therapeutics AB News
P0F FAQ
What was Egetis Therapeutics AB’s price range in the past 12 months?
Egetis Therapeutics AB lowest stock price was $0.36 and its highest was $0.73 in the past 12 months.
What is Egetis Therapeutics AB’s market cap?
Egetis Therapeutics AB’s market cap is €345.93M.
When is Egetis Therapeutics AB’s upcoming earnings report date?
Egetis Therapeutics AB’s upcoming earnings report date is Nov 06, 2026 which is in 36 days.
How were Egetis Therapeutics AB’s earnings last quarter?
Egetis Therapeutics AB released its earnings results on Aug 21, 2026. The company reported -$0.022 earnings per share for the quarter, missing the consensus estimate of -$0.013 by -$0.008.
Is Egetis Therapeutics AB overvalued?
According to Wall Street analysts Egetis Therapeutics AB’s price is currently Undervalued.
Does Egetis Therapeutics AB pay dividends?
Egetis Therapeutics AB does not currently pay dividends.
What is Egetis Therapeutics AB’s EPS estimate?
Egetis Therapeutics AB’s EPS estimate is -0.02.
How many shares outstanding does Egetis Therapeutics AB have?
Egetis Therapeutics AB has 464,947,240 shares outstanding.
What happened to Egetis Therapeutics AB’s price movement after its last earnings report?
Egetis Therapeutics AB reported an EPS of -$0.022 in its last earnings report, missing expectations of -$0.013. Following the earnings report the stock price went down -2.504%.
Which hedge fund is a major shareholder of Egetis Therapeutics AB?
Currently, no hedge funds are holding shares in DE:P0F
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Egetis Therapeutics AB
Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
P0F Stock 12 Month Forecast
Average Price Target
$2.91